The systemic treatment of recurrent ovarian cancer revisited
Copyright © 2021. Published by Elsevier Ltd..
Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically driven algorithm. Nowadays, platinum-based chemotherapy should be offered to all patients with a reasonable chance of responding to this therapy. The treatment-free interval for platinum is only one of many factors affecting patients' eligibility for platinum re-treatment. Bevacizumab increases the response to chemotherapy irrespective of the cytotoxic regimen and can be valuable in patients with an urgent need for symptom relief (e.g. pleural effusion, ascites). For patients with recurrent high-grade ovarian cancer, which responds to platinum-based treatment, maintenance therapy with a poly(ADP-ribose) polymerase inhibitor can be offered, regardless of the BRCA mutation status. Here we review contemporary decision-making processes in the systemic treatment of relapsed ovarian cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 32(2021), 6 vom: 15. Juni, Seite 710-725 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baert, T [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.05.2021 Date Revised 24.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2021.02.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322331862 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322331862 | ||
| 003 | DE-627 | ||
| 005 | 20231225181820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2021.02.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322331862 | ||
| 035 | |a (NLM)33675937 | ||
| 035 | |a (PII)S0923-7534(21)00155-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baert, T |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The systemic treatment of recurrent ovarian cancer revisited |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2021 | ||
| 500 | |a Date Revised 24.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
| 520 | |a Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically driven algorithm. Nowadays, platinum-based chemotherapy should be offered to all patients with a reasonable chance of responding to this therapy. The treatment-free interval for platinum is only one of many factors affecting patients' eligibility for platinum re-treatment. Bevacizumab increases the response to chemotherapy irrespective of the cytotoxic regimen and can be valuable in patients with an urgent need for symptom relief (e.g. pleural effusion, ascites). For patients with recurrent high-grade ovarian cancer, which responds to platinum-based treatment, maintenance therapy with a poly(ADP-ribose) polymerase inhibitor can be offered, regardless of the BRCA mutation status. Here we review contemporary decision-making processes in the systemic treatment of relapsed ovarian cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a platinum re-treatment | |
| 650 | 4 | |a platinum-based chemotherapy | |
| 650 | 4 | |a poly(ADP-ribose) polymerase (PARP) inhibitor | |
| 650 | 4 | |a recurrent ovarian cancer | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Ferrero, A |e verfasserin |4 aut | |
| 700 | 1 | |a Sehouli, J |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donnell, D M |e verfasserin |4 aut | |
| 700 | 1 | |a González-Martín, A |e verfasserin |4 aut | |
| 700 | 1 | |a Joly, F |e verfasserin |4 aut | |
| 700 | 1 | |a van der Velden, J |e verfasserin |4 aut | |
| 700 | 1 | |a Blecharz, P |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, D S P |e verfasserin |4 aut | |
| 700 | 1 | |a Querleu, D |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, N |e verfasserin |4 aut | |
| 700 | 1 | |a du Bois, A |e verfasserin |4 aut | |
| 700 | 1 | |a Ledermann, J A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 32(2021), 6 vom: 15. Juni, Seite 710-725 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:6 |g day:15 |g month:06 |g pages:710-725 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2021.02.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 6 |b 15 |c 06 |h 710-725 | ||